Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
Puglisi
Fabio
F
de Azambuja
Evandro
E
de Castro
Gilberto
G
Demonty
Gaston
G
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D018579:Patient Selection; D011379:Prognosis; D012494:Sampling Studies; D016019:Survival Analysis; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015251:Epirubicin; D003520:Cyclophosphamide; D000068878:Trastuzumab; D017239:Paclitaxel; D005472:Fluorouracil